Gray, Juliet - University of Southampton

个人简介

Dr Gray graduated from Cambridge University and the Royal Free Hospital School of Medicine. She completed her clinical training in Paediatric Oncology at Southampton, Great Ormond Street and the Royal Marsden hospitals. During her training she was awarded a Cancer Research UK Clinical Research Fellowship, which allowed her to complete a PhD in cancer immunotherapy within the Cancer Sciences Unit, University of Southampton. In 2006, she was appointed at a Walport Clinical Lecturer in Paediatric Oncology, and as a Senior Lecturer in Paediatric Oncology in 2010. She is an honorary Consultant in Paediatric Oncology at University Hospital Southampton NHS Foundation Trust (UHSFT). Dr Gray is a member of the NCRI Children’s Cancer and Leukaemia CSG Neuroblastoma Subgroup, the SIOP European Neuroblastoma Research Network and the UK Children’s Cancer and Leukaemia Group (CCLG) New Agents Group. She is the CCLG Clinical Trial Lead for the Southampton Paediatric Oncology Principal Treatment Centre, Chair of the Southampton Paediatric Chemotherapy Group and a member of UHSFT Drugs Committee.

研究领域

Dr Gray’s main research interest is in the development of new immunotherapies to treat neuroblastoma, one of the commonest childhood cancers. Neuroblastoma is a tumour of neuroectodermal origin that usually develops in very young children. Unfortunately in the majority of children the disease is metastatic by the time of diagnosis, and survival rates for these children remain poor despite intensive conventional therapies. Toxicity from these therapies is significant and new therapies are needed to improve outcome. Immunotherapy is an attractive therapeutic option for these children because it potentially offers a highly specific way of targeting neuroblastoma cells and sparing normal tissues. Evidence of spontaneous anti-neuroblastoma immune responses is found in most children with the disease, but in general these endogenous responses are weak and fail to control disease. Monoclonal antibodies targeting the GD2 antigen have already shown clinical benefit in children with neuroblastoma, and one focus of Dr Gray’s work is aimed at understanding how these antibodies work, in order to optimise and improve their therapeutic effect. The other major focus of Dr Gray’s work is on using immunomodulatory monoclonal antibodies to generate therapeutic anti-neuroblastoma immunity. She has found that several of these agents (anti-4-1BB, anti-CTLA-4 and anti-CD40) show very promising effects in pre-clinical neuroblastoma models, with eradication of established disease and long-term survival. In more aggressive models, although these antibodies are not effective as single agent, combining them with peptide vaccination provides successful long-term therapy. Current work is establishing which combination of these antibodies and peptide vaccines is most potent, and it is anticipated that this will be taken forward to Phase I trial in children in the near future. Finally, Dr Gray’s is investigating the immune response to vaccination in children who are receiving chemotherapy. She is Chief Investigator of a multi-centre study investigating whether pneumococcal conjugate vaccines can be used to generate effective anti-pneumococcal immunity in children receiving chemotherapy for Acute Lymphoblastic Leukaemia. The centre will recruit 120 children from 7 paediatric oncology centres and is funded by a NIHR Research for Patient Benefit grant.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy - Chowdhury, Ferdousi, Dunn, Stuart, Mitchell, Simon, Mellows, Toby, Ashton-Key, Margaret and Gray, Juliet Published:2015Publication:OncoImmunologyVolume:4, (10)doi:10.1080/2162402X.2015.1029701 Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy - Marabelle, Aurelien and Gray, Juliet Published:2015Publication:Pediatric Blood & CancerVolume:62, (8)Page Range:1317-1325doi:10.1002/pbc.25508PMID:25808079 Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood - Chowdhury, Ferdousi, Lode, Holger N., Cragg, Mark S., Glennie, Martin J. and Gray, Juliet C. Published:2014Publication:Cancer Immunology, ImmunotherapyVolume:63, (6)Page Range:559-569doi:10.1007/s00262-014-1534-yPMID:24658837 Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood - Chowdhury, F., Lode, H.N., Cragg, M.S., Glennie, M.J. and Gray, J.C. Published:2014Publication:Cancer Immunology ImmunotherapyVolume:63, (6)Page Range:559-569doi:10.1007/s00262-014-1534-yPMID:24658837